Researchers are developing new MRI contrast agents that are activated in low oxygen environments enabling improved diagnosis and treatment of hypoxic tumors as well as other diseases.
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
